VRTXHealthcare · BiotechnologyThe 29 Wall Street analysts covering Vertex Pharmaceuticals, Inc. hold a median 12-month price target of $573 — +19.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 4 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Vertex Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (27): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Vertex Pharmaceuticals, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on VRTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +19.6% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2026 | Truist Securities | Maintains | Buy | $542 → $560 |
| 13 July 2026 | UBS | Maintains | Buy | $545 → $585 |
| 7 July 2026 | Baird | Maintains | Underperform | $330 → $350 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $543 → $570 |
| 6 May 2026 | Barclays | Maintains | Overweight | — |
| 5 May 2026 | Bernstein | Maintains | Outperform | — |
| 5 May 2026 | Canaccord Genuity | Maintains | Hold | — |
| 5 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 5 May 2026 | RBC Capital | Maintains | Outperform | — |
| 30 Apr 2026 | Canaccord Genuity | Maintains | Hold | — |
| 10 Apr 2026 | Morgan Stanley | Maintains | Overweight | — |
| 18 Mar 2026 | Maxim Group | Upgrade | Buy | — |
| 11 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 10 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 10 Mar 2026 | Citigroup | Maintains | Buy | — |
| 10 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Mar 2026 | Jefferies | Initiates | Buy | — |
| 10 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
| 10 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 17 Feb 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 15% of US stocks
Cheaper than 17% of US stocks
Cheaper than 13% of US stocks
Higher than 48% of US stocks
Higher than 80% of US stocks
Higher than 95% of US stocks
Higher than 92% of US stocks
Higher than 92% of US stocks
Higher than 85% of US stocks
Higher than 95% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRTX appears on the weeks it earns a place.
Vertex Pharmaceuticals stock ticked higher on Tuesday. The company reported double-digit sales growth, though net profit growth was more modest.
Why it matters — A VRTX watcher would care because strong sales growth signals healthy business momentum, while modest profit growth and other developments worth monitoring could affect the company's outlook.
Vertex's Q2 earnings missed estimates, though its revenues beat expectations. The company also raised its 2026 sales outlook and noted growing contributions from newer products.
Why it matters — VRTX watchers would care because the revenue beat and upgraded 2026 outlook point to growing momentum from newer products even as quarterly earnings came in below estimates.
On its Q2 earnings call, Vertex raised its 2026 revenue outlook, citing CF growth, newer products, and a near-term renal launch as factors strengthening its diversification efforts.
Why it matters — A VRTX watcher would care because the raised 2026 outlook signals management's confidence in CF growth, newer products, and its expanding pipeline beyond cystic fibrosis.
Vertex Pharmaceuticals is undergoing a transition year, evolving from a cystic-fibrosis-focused biotech into a multi-franchise growth platform. Second-quarter 2026 revenue rose 12% to $3.33 billion, with strong CF performance and early scaling of Casgevy and Journvax supporting raised FY26 guidance of $13.1–$13.2 billion, as the company reinvests its $13.6 billion cash position and diversifies through the Crinetics acquisition.
Why it matters — The item signals that Vertex is broadening beyond cystic fibrosis with new commercial franchises (Casgevy, Journvax), a raised full-year guidance, and pipeline and M&A-driven growth that VRTX watchers would want to track.
Vertex Pharmaceuticals held its Q2 2026 earnings call, with the transcript published by Seeking Alpha.
Why it matters — The earnings call transcript provides VRTX watchers with management's discussion of the company's quarterly financial performance and business outlook.
The 29 Wall Street analysts covering Vertex Pharmaceuticals, Inc. have a median 12-month price target of $573, with estimates ranging from $350 to $652. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 29 analysts covering Vertex Pharmaceuticals, Inc., 23 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Vertex Pharmaceuticals, Inc. 65 out of 100 across roughly 4,600 US stocks as at 4 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Aug 2026, Vertex Pharmaceuticals, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 29 analysts implies +19.6% from the last close, and Ticker Nerd's factor model ranks Vertex Pharmaceuticals, Inc. 65 out of 100 as at 4 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vertex Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $350 to $652 over the next 12 months.
Vertex Pharmaceuticals, Inc. returned +1.4% over the 12 months to 4 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative medicines for serious diseases. The company is best known for its leadership in cystic fibrosis, where it markets a portfolio of CFTR modulator therapies such as Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco and Alyftrek that address underlying genetic defects in eligible patients across multiple age groups.
The most recent item we track (The Motley Fool, 4 Aug 2026): "Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday". Vertex Pharmaceuticals stock ticked higher on Tuesday. The company reported double-digit sales growth, though net profit growth was more modest.
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative medicines for serious diseases. The company is best known for its leadership in cystic fibrosis, where it markets a portfolio of CFTR modulator therapies such as Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco and Alyftrek that address underlying genetic defects in eligible patients across multiple age groups. Beyond cystic fibrosis, Vertex today provides and develops treatments for sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain, as well as investigational therapies for APOL1-mediated kidney disease and other severe conditions. Headquartered in Boston, Massachusetts and founded in 1989, Vertex operates across the United States, Europe, and internationally, serving specialized markets through a combination of proprietary drug development, advanced research collaborations, and global commercialization capabilities. Its portfolio positions the company as a key player in specialty care within the broader healthcare and biotechnology sectors.
CEO Dr. Reshma Kewalramani FASN, M.D. · 6,400 employees · United States · https://www.vrtx.com